Process
Getting started is a short online quiz followed by a same-day provider review, according to AvataCore’s site. If a provider determines GLP-1 therapy is appropriate, the patient chooses a weekly injection, a daily oral tablet, or a dual-action GLP-1/GIP injection, and medication ships within 1 to 2 days. If the provider determines the patient isn’t a candidate after the consultation, AvataCore states it issues a full refund of the first payment.

Treatment Effectiveness
AvataCore’s own marketing cites body-weight reduction percentages from published clinical trials of brand-name tirzepatide and semaglutide, noting these are clinical-trial populations on brand-name medication and that individual results, including AvataCore’s own patients, may differ. We’re not repeating those specific percentages here since they describe a different product than the compounded medication AvataCore actually dispenses; AvataCore states outcomes are never guaranteed and results vary by individual.
Additional Features
Plans include free dietician visits and care coaching alongside the prescribed medication, according to AvataCore’s site. The company also states its standard monthly rate doesn’t increase if your dose is adjusted, and offers a dual-action GLP-1/GIP injection option for patients whose provider determines a single-pathway GLP-1 isn’t giving them the results they want.

Ease of use
The path to treatment is a short quiz that AvataCore describes as free and requiring no credit card, followed by a same-day provider review. Patients can choose between a weekly injection, a daily oral tablet, or a weekly dual-action injection, and AvataCore states the subscription can be canceled anytime from the patient portal or by email.

Post-treatment Support
AvataCore states it offers phone and email support, and provides free dietician visits and care coaching as part of the plan. We didn’t find a stated live chat option on the pages we reviewed.
Safety
AvataCore discloses that its compounded semaglutide and tirzepatide carry the same boxed warning as the FDA-approved formulations, for risk of thyroid C-cell tumors, and are contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. AvataCore states compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality, and that formulation, strength, inactive ingredients, and clinical effects may differ from FDA-approved branded versions. Clinical evaluations and prescribing decisions are made by OpenLoop Health’s licensed providers, not by AvataCore directly.
Thank you!